TABLE 1

Demographic and clinical characteristics of patients with hVISA bacteremia, according to treatment outcomea

CharacteristicDeceased patients (n = 38)Surviving patients (n = 83)All patients (n = 121)P value
Age (yr), median (IQR)64.5 (57–71)66 (54–73)65 (55–72)0.888
Male27 (71.1)64 (77.1)91 (75.2)0.474
Site of acquisition
    Community acquired2 (5.3)3 (3.6)5 (4.1)0.649
    Health care associated4 (10.5)15 (18.1)19 (15.7)0.218
    Nosocomial32 (84.2)65 (78.3)97 (80.2)0.450
Underlying disease/condition
    Solid tumor27 (32.5)18 (47.4)45 (37.2)0.087
    Hematologic malignancy4 (10.5)1 (1.2)5 (4.1)0.033
    Diabetes mellitus7 (18.4)29 (34.9)36 (29.8)0.065
    End-stage renal disease4 (10.5)10 (12.0)14 (11.6)>0.999
    Liver cirrhosis4 (10.5)9 (10.8)13 (10.7)>0.999
    Neutropenia1 (2.6)2 (2.4)3 (2.5)>0.999
    Immunosuppressant use14 (36.8)17 (20.5)31 (25.6)0.056
    Recent chemotherapy3 (7.9)4 (4.8)7 (5.8)0.677
McCabe and Jackson criteria
    Ultimately or rapidly fatal diseaseb19 (50.0)21 (25.3)40 (33.1)0.007
Charlson comorbidity index, median (IQR)3 (2–5)2 (1–4)3 (2–4)0.140
APACHE II score, median (IQR)20 (16–28)16 (11–21)17 (11–23)0.013
Pitt bacteremia score, median (IQR)2 (0–6)1 (0–2)1 (0–3)0.010
Septic shock14 (36.8)7 (8.4)21 (17.4)<0.001
Type of infection
    Persistent bacteremia (≥7 days)10 (26.3)27 (32.5)37 (30.6)0.491
    Metastatic infection7 (18.4)19 (22.9)26 (21.5)0.578
    Infective endocarditis5 (13.2)7 (8.4)12 (9.9)0.514
    Catheter-related infection18 (47.4)41 (49.4)59 (48.8)0.836
    Pneumonia6 (15.8)5 (6.0)11 (9.1)0.098
    Skin and soft tissue infection1 (2.6)5 (6.0)6 (5.0)0.664
    Bone and joint infection1 (2.6)5 (6.0)6 (5.0)0.664
    Postoperative wound infection2 (5.3)7 (8.4)9 (7.4)0.718
    Primary bacteremia5 (13.2)8 (9.6)13 (10.7)0.544
  • a Data are presented as the number of patients (with the corresponding percentage shown in parentheses), unless otherwise specified. IQR, interquartile range.

  • b Of 121 patients, only 1 person had rapidly fatal disease.